Merck & Company Inc (MRK)vsVale SA ADR (VALE)
MRK
Merck & Company Inc
$119.37
+2.58%
HEALTHCARE · Cap: $287.71B
VALE
Vale SA ADR
$15.14
+1.82%
BASIC MATERIALS · Cap: $64.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Vale SA ADR generates 229% more annual revenue ($213.59B vs $65.01B). MRK leads profitability with a 28.1% profit margin vs 6.5%. MRK appears more attractively valued with a PEG of 3.49. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
VALE
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-141.2%
Fair Value
$49.50
Current Price
$119.37
$69.87 premium
Margin of Safety
-47.9%
Fair Value
$11.75
Current Price
$15.14
$3.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 27.6%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Moderate valuation
0.5% revenue growth
ROE of 5.9% — below average capital efficiency
6.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VALE
The strongest argument for VALE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VALE
The primary concerns for VALE are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
VALE carries more volatility with a beta of 0.94 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 55/100), backed by strong 28.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vale SA ADR
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Vale SA produces and sells iron ore and iron ore pellets for use as raw material in steelmaking in Brazil and internationally. The company is headquartered in Rio de Janeiro, Brazil.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?